GlassScriptPhysician profile
Eldena Borovina
NPI 1326640038
$1,302.73
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,287 · 2022: $15.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $389.82 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.71 | 2021 | |
| Redhill Biopharma INC. | $135.25 | 2021 | |
| Collegium Pharmaceutical, INC. | $107.83 | 2021 | |
| Scilex Pharmaceuticals INC. | $74.28 | 2021 | |
| Biodelivery Sciences International, INC. | $67.77 | 2021 | |
| Nevro Corp. | $66.43 | 2021 | |
| Boston Scientific Corporation | $65.99 | 2021 | |
| Abbvie INC. | $54.29 | 2021-2022 | |
| Bioventus LLC | $32.64 | 2021 | |
| Lilly USA, LLC | $31.55 | 2021 | |
| Uswm, LLC | $30.67 | 2021 | |
| Almatica Pharma LLC | $23.76 | 2021 | |
| Lundbeck LLC | $18.74 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eldena Borovina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.